{"name":"UNION therapeutics","slug":"union-therapeutics","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"Negative Control","genericName":"Negative Control","slug":"negative-control","indication":"Other","status":"marketed"},{"name":"ATx201 Gel 2%","genericName":"ATx201 Gel 2%","slug":"atx201-gel-2","indication":"Other","status":"phase_2"},{"name":"ATx201 Gel 4%","genericName":"ATx201 Gel 4%","slug":"atx201-gel-4","indication":"Other","status":"phase_1"},{"name":"ATx201 dermal formulations 2%","genericName":"ATx201 dermal formulations 2%","slug":"atx201-dermal-formulations-2","indication":"Other","status":"phase_1"},{"name":"Orismilast modified release tablets","genericName":"Orismilast modified release tablets","slug":"orismilast-modified-release-tablets","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Positive Control","genericName":"Positive Control","slug":"positive-control","indication":"Metastatic non-small cell lung cancer, PD-L1 positive","status":"marketed"}]}],"pipeline":[{"name":"Positive Control","genericName":"Positive Control","slug":"positive-control","phase":"marketed","mechanism":"Positive control drug used to validate the efficacy of other treatments.","indications":["Metastatic non-small cell lung cancer, PD-L1 positive"],"catalyst":""},{"name":"Negative Control","genericName":"Negative Control","slug":"negative-control","phase":"marketed","mechanism":"A negative control is an inactive or placebo substance used in clinical trials to establish baseline effects and validate that observed outcomes are due to the active drug rather than other factors.","indications":[],"catalyst":""},{"name":"ATx201 Gel 2%","genericName":"ATx201 Gel 2%","slug":"atx201-gel-2","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ATx201 Gel 4%","genericName":"ATx201 Gel 4%","slug":"atx201-gel-4","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ATx201 dermal formulations 2%","genericName":"ATx201 dermal formulations 2%","slug":"atx201-dermal-formulations-2","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Orismilast modified release tablets","genericName":"Orismilast modified release tablets","slug":"orismilast-modified-release-tablets","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxPVnZGYTBfR3o4czAtRFJXU1dwX190aXBvd3dCVUhxUnZXekRSeDR1TmN4ZkpHZWhVSlVBcWNVNXlXYmVQamUzWm9UR0hfY0pkaDNzV0NPdGV1aXFDREEzTGZTOUk0aEppbk9GUGs5b3R6MGdOOHR4djRLTkh2OW1Ub2t0dGh6SUV5VEctOFpOTzRHb05OSmRSVUQzRjhOOEZpZ3hfQ1hONzk0dm9xeEZqeTczSFBoWjllakRONGEzRzI1RDAxMlF6NmM3b0JYajJBWG1oU3dPczFZTkt6a3ZFeU5ER1pkZ0t6S21KVnUzVjhfRV9qRGJNb01HNkVUSVNIV0pmdEU4YU9fcGJBWmU0?oc=5","date":"2026-02-16","type":"pipeline","source":"PR Newswire","summary":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight - PR Newswire","headline":"Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | Delve","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxQaURFcnZTOVJqMThmdkR6ZFNKWFhxRFhtX3JseDBXTE8yQkdWTzdHaVcxUEI4V09PYjl4RnRERmNPY0tUYnQyTkhiTnRsYTFBTkZjblltYnhobkRvWWhvVXhseEdtRW5SNk04M3dqUjVSZ2RweUlyUkh6OVptdTVCZGEtcEN3RmtyNGc5NWJmblY3VUpKa2RDUk1QcGxkSjduRTVJWHlGOG51djNyWjE2Q25fRTJldlQwUnlxTWxjRzJzQjJfbThqREFkZjB3a0tRUEdqcjN3eG8yVW9BTy1JSmxfTlpOa3d6S19BYTdSRjdLZw?oc=5","date":"2026-02-11","type":"pipeline","source":"BioSpace","summary":"Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar - BioSpace","headline":"Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Unipha","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxQTmZBbG9pTlFLM1BhQU9KNkk0M0sxNmFzd0g1bmZzZHUzUVFCWWNiTVhZeWRFdFh3aGJjVDN3ZHhkcVBZWkgzOTVIQ19UNnl6UU45ODVKeHdwOTByZlE2cWx1TW8yMDM1VFhKSk9hc0FzZ1VwTDRncng3blhOQjdaVVJOS3N6TTY2bl9lQkx6RHhpTTZTZkxueUx5b2RMbmdNSjNLdGtFSC1xeGtBRVVRRkUyUmZnS3BxUlN4amJn?oc=5","date":"2026-02-10","type":"pipeline","source":"Fraser Institute","summary":"Timely Access to New Pharmaceuticals in Canada, the United States, and the European Union, 2026 - Fraser Institute","headline":"Timely Access to New Pharmaceuticals in Canada, the United States, and the European Union, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE1kNThzU1RrU09sakFCdlJaOXVVZnZhcjg2OXpIajhaMEk4N25DaF95YXo0Tk9ZakdYRl92bnBLcXZmdkZJaG1YZzVCSFVmSFRmdHpybHhTMEdVQTJQZFNDb1dXYzExZw?oc=5","date":"2025-10-30","type":"pipeline","source":"MedPage Today","summary":"Novel Oral miR-124 Enhancer Improves Remission in Refractory UC - MedPage Today","headline":"Novel Oral miR-124 Enhancer Improves Remission in Refractory UC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxNbURGeFBVM19lWjJINGlwR01HamQ5X2traTA5bllxU0gyWkd6M21MeElyZXhHTzR2LUhvZ0tsbmNzZXVoVFp0bTc0a1pNZmxDaDFNTkxXT2RWNVpYZG5CZWpBYWNGNTVPVUVGQzJwYUY2YWpTb2hWMGJDSU5tUE9OMmlHOHNScHZDM3ZZRE5YXzFRTXZzT1BkYVFKWUlNN2g1YTh1aHJKN1h3eTJ2cTFFdzdVbnVHV05EWDQ0SVB6VEZDOFdkQzU2QUhyQXRXT3BmbDY0eDllY0R6LUhNaHo0dkU0dWtNUjJ5OGFteEdSUzM4SWlZVVRnX2ZDUWFMZmRKVmZXRllhZDNHN3QzLVRabWZERlhTV0JCTWdaQ1JUdmpqbkY5OHpNb053SUdRUQ?oc=5","date":"2025-10-23","type":"trial","source":"globenewswire.com","summary":"Hidradenitis Suppurativa Clinical Trial Analysis: Key - globenewswire.com","headline":"Hidradenitis Suppurativa Clinical Trial Analysis: Key","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQRmJ4NUJuTnh0VzlBTkF6a1BFcDNMaG5QTFB3YnpvMl9QWG9lV1hpMmdXYXJEOGNVVjF0ZkxwMGZDZW5STldsdTFkTG5VRnhBOHp5UWh2bFljeS1sN1RFVEVxLU1TR3pqWGxRd0xvanlmSjBqMDZOaHE3SGlTT0lPMEZrUWJ0Z1l1QlhNQnlTbWpPQ3dkVURGN2JIU1k?oc=5","date":"2025-10-20","type":"regulatory","source":"Yahoo Finance","summary":"Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union - Yahoo Fin","headline":"Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulator","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNNDIyTDZZd2pqcXRKTVh2cHdSLU1LYm9qcnF4SkQ1S1U2eEpKbVE1Y0VTbHVKQlNYakk2ZTNadm9UX0wxMVRJUWhtMF9sY3BMSW1nUXR5X2FqZDd1RmJqQ3p6NkRSM2lKdFRPc1lTdWRzamhWY1praXEyN083LU14NFVDN2xMY3NZMzFJU0hRRVZkUWxTc3l0OUFBQ25vTDYySjNsLW5pMDhaMjJjZFBVNmtjVQ?oc=5","date":"2025-10-15","type":"pipeline","source":"The Pharma Letter","summary":"AI-first MindMaze emerges from $1.1 billion union of Relief and NeuroX - The Pharma Letter","headline":"AI-first MindMaze emerges from $1.1 billion union of Relief and NeuroX","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTE1ydVRZNHNuNVI4NDVNaTdMaTRSUnNkVXRiZ1pkdDZfNVVocmNPR1JjTl9ucllqeFZPSUJBak5yQnJ0QmFXM3p3eV9Mc0xOU1VVc1BWakpaMWo1WEJnRmdTX1QzRFRKQTlu?oc=5","date":"2025-09-19","type":"pipeline","source":"Wiley Online Library","summary":"Orismilast, a Potent and Selective PDE4B/D Inhibitor, Reduces Protein Levels of Key Disease Driving Cytokines in the Skin of Patients With Plaque Psoriasis - Wiley Online Library","headline":"Orismilast, a Potent and Selective PDE4B/D Inhibitor, Reduces Protein Levels of Key Disease Driving Cytokines in the Ski","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQT2RYbXVMSkUxUGVnMmprU01ILUlzckJkanJFQlBfTlFZTVh2SlRUc0d3S1h0eWpZeHE5S2lOZElaOHZXeGRWMUxINnVrSmljeTJ3RHNEcWt0WU1PTjhBZnI3STVRUXpUMUVXVjZQSkczdGNzMmpvSUl5am5DUmd1ZEdjTUwzVERCYjZPWDFub0h3QVVEc0NxWW9Kai1kYWE5MFcxRTB1QzAxU2lhRXdGNUFn?oc=5","date":"2025-09-14","type":"pipeline","source":"Ministerio de Relaciones Exteriores de Cuba","summary":"Cuban Ambassador to Egypt visits Medical Union Pharmaceutical facilities - Ministerio de Relaciones Exteriores de Cuba","headline":"Cuban Ambassador to Egypt visits Medical Union Pharmaceutical facilities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOcW9sellPVlVVRjc2VFF3WTlsa1BaTDhuTlhJV0dvX0tScm9XZVFubTZCXzVEVzBHblAtQUpySVNrR3NrQ0RNTUJrNWpVY1lFaXFOY2xHeVNjbWdUclJQMjZWaHp6aXphMUlPSUM2X1VGNnNmU3ZzRW5MYnV6V0pJbk11SXhIYy04YnZvd3FZdHRkZTFvNzJGOEp6YzczcE5GNE5tR2VYaw?oc=5","date":"2025-08-07","type":"trial","source":"Clinical Trials Arena","summary":"Clinical trial supply chains in the US navigate pharma tariffs - Clinical Trials Arena","headline":"Clinical trial supply chains in the US navigate pharma tariffs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQbDU3UEIxakNQV3ByVXlRNzhMMTZvZVdXVFNuV1JrRUNGVzFnYk5QYTNtbDhiV1VMajZmbWdBRXdvLVlBNkZFdlBpVHFidk54bDh3bFhXNzU4aVNqTDAwbVRZckJMWFdFY0F1U05ndGxKS21HMU5pTDNOV3FTTnBwb1A1ZlFZazg?oc=5","date":"2025-08-07","type":"pipeline","source":"Newsweek","summary":"Europe to Escape New Trump Pharmaceutical Tariffs - Newsweek","headline":"Europe to Escape New Trump Pharmaceutical Tariffs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMib0FVX3lxTFBlMEhIUXp4TTh3R2p4MHJwbDJ6TW8yVjNORFI0VGVycUtVUG5hYlJYXzJaMWFqaHowNDV1dmZVa3BkMEx2LUljUEN0RThEVXJxLUhRTDN5VGtzN0hJM1hSd1RzdDhLSmp6bV84UW9jVQ?oc=5","date":"2025-07-04","type":"pipeline","source":"medwatch.com","summary":"Utility Therapeutics sold to global pharma player: \"A dream come true\" - medwatch.com","headline":"Utility Therapeutics sold to global pharma player: \"A dream come true\"","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"marketed":2,"phase_2":2,"phase_1":2},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}